Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( <scp>YUSHIMA</scp> Study)
Higher serum albumin levels were significantly associated with EV-induced PN. Appropriate dose reduction may help prevent progression from Grade 2 to Grade 3 PN. Nevertheless, further prospective studies are warranted to determine the optimal dose management strategy for long-term EV therapy.
Authors
- Ryo Kitabayashi (ORCID: https://orcid.org/0000-0001-5807-0659)
- Yuya Maezawa (ORCID: https://orcid.org/0009-0008-0913-8416)
- Naoko Kawamura (ORCID: https://orcid.org/0000-0001-9517-7543)
- Takahiko Soma (ORCID: https://orcid.org/0000-0002-7086-8214)
- Keita Izumi (ORCID: https://orcid.org/0000-0002-9785-6432)
- Soichiro Yoshida
- Sho Uehara (ORCID: https://orcid.org/0000-0001-9579-2992)
- Fumitaka Koga
- Ryoji Takazawa
- Noboru Numao
- Takanobu Yamamoto
- Saori Araki
- Yusuke Nakamura (ORCID: https://orcid.org/0009-0004-6320-7030)
- Atsushi Yoshinaga
- Yasuhisa Fujii
- Masahiro Toide
- Kenji Tanabe
- Masaharu Inoue
- Hajime Tanaka
- Akihiro Hirakawa
Institutions
- Tokyo Metropolitan Komagome Hospital (JP)
- Tokyo Metropolitan Ohtsuka Hospital (JP)
- Tsuchiura Kyodo General Hospital (JP)
- Showa General Hospital (JP)
- JA Toride Medical Center (JP)
- Saitama Cancer Center (JP)
- Ichikawa City Rehabilitation Hospital (JP)
- The Cancer Institute Hospital (JP)
- Saitama Red Cross Hospital (JP)
- Soka Municipal Hospital (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- Institute of Science Tokyo (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1111/iju.70329
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01